Fravit

Method of action: Vitamins

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fravit

Property	Description
Active Ingredient	Dihydrotachysterol and Vitamin A (Retinol)
Form	Oral Solution (drops) or Capsules
Pharmacological Class	Vitamin D Analogue, Retinoid (Fat-Soluble Vitamin)
Common Function	Calcium Regulation and Mineral Homeostasis
Origin	Synthetic (Dihydrotachysterol) and Essential Micronutrient (Vitamin A)

Fravit: Classification and Active Ingredients

Fravit is a prescription-only medication classified as a combination product, uniting two distinct fat-soluble vitamins and their derivatives: Dihydrotachysterol and Vitamin A (Retinol). The formulation is intended for oral administration, typically presented as an oral solution or in capsules.

Fravit is structurally positioned as a Vitamin D Analogue and Retinoid combination, a class clinically recognized for its essential role in skeletal and metabolic function. The primary component, Dihydrotachysterol (DHT), is a synthetic, modified molecule of Vitamin D. The co-formulated active ingredient, Vitamin A, is an essential Retinoid necessary for supporting critical physiological functions, including tissue integrity.

Dihydrotachysterol's Distinctive Properties

The component Dihydrotachysterol functions as a highly potent Calcium Regulator due to a specific structural modification. Its key differentiating feature is its unique metabolic route: Dihydrotachysterol primarily requires activation by the liver but is subsequently effective without needing the secondary hydroxylation step normally performed by the kidneys.

This distinct activation pathway allows DHT to maintain reliable control over the body’s calcium and phosphate levels. This promotes the consistent stimulation of intestinal absorption and bone mobilization, which can be particularly advantageous for supporting mineral balance.

General Purpose: Supporting Mineral Homeostasis

The general purpose of Fravit is to provide robust support for mineral homeostasis, the physiological balance of calcium and phosphate in the blood and tissues. The primary action involves enhancing the body's ability to absorb and retain calcium, which is crucial for nerve, muscle, and heart function.

By regulating the systemic flow of these essential minerals, this medication acts as a specialized aid targeted at establishing stability in the internal mineral environment. The overall benefit is the comprehensive support of skeletal health and the efficient operation of numerous mineral-dependent processes.

What side effects are possible with Fravit?

Possible Side Effects and Safety Information for Fravit

Fravit's safety profile, established through clinical trials and post-market surveillance, is formally documented by regulatory authorities (such as the FDA or EMA) to categorize and communicate known risks. Information on adverse events is consistently structured based on the System-Organ Class (SOC) and by frequency of occurrence, following international guidelines.

Adverse Reactions Summary

Classification	Frequency (%)	Examples of Affected Body Systems (SOC)
Very Common	10% (at least 1 in 10 patients)	General Disorders, Administration Site Conditions
Common	1% to < 10% (at least 1 in 100 patients)	Gastrointestinal Disorders, Nervous System Disorders
Uncommon	0.1% to < 1% (at least 1 in 1,000 patients)	Skin and Subcutaneous Tissue Disorders
Rare/Very Rare	< 0.1% (less than 1 in 1,000 patients)	Blood and Lymphatic System Disorders

Serious and Clinically Significant Risks

Official regulatory documentation identifies certain events as serious adverse reactions. These are events that result in outcomes such as death, life-threatening conditions, or require inpatient hospitalization. All serious events, regardless of frequency, are highlighted in the safety information to ensure awareness. Examples of clinically significant risks, which may include severe hypersensitivity or specific organ toxicities, are documented in the Warnings and Precautions section of the drug’s labeling.

Safety Considerations and Restrictions

Fravit’s label includes Contraindications that identify situations or patient populations where the drug must not be used because the associated risks are deemed to outweigh any potential benefit. Additional Warnings and Precautions define specific conditions or patient groups—such as pediatric or patients with pre-existing hepatic or renal impairment—who may be at a higher risk and require particular monitoring during therapy. Dose-related safety patterns are noted only where a clear relationship between the dose level or cumulative exposure and the incidence or severity of an adverse reaction has been explicitly established in the regulatory data.

Overdose and Emergency Response

The regulatory descriptions of Fravit overdose focus on the combined toxicities of its components: Hypercalcemia, derived from the Vitamin D analogue Dihydrotachysterol, and Hypervitaminosis A from Retinol.

Overdose manifestations are documented to involve multi-system effects. Initial signs of overdose may include headache, anorexia, excessive thirst (polydipsia) and urination (polyuria), metallic taste, nausea, vomiting, and unusual weakness or fatigue. Neurological effects such as mental confusion, blurred vision, and lack of coordination (ataxia) are also recognized.

The official labeling identifies severe or life-threatening outcomes, including widespread soft tissue calcification involving the heart, blood vessels, and kidneys, which may lead to renal insufficiency or cardiac arrhythmias. Increased intracranial pressure, seizures, and coma are also documented as severe manifestations.

Regulatory guidance states that suspected overdose requires the immediate withdrawal of Fravit. Urgent medical attention must be sought for signs of a severe allergic reaction or for any signs indicative of a hypercalcemic crisis (e.g., stupor, coma, severe dehydration). Supportive management consists of bed rest, a low-calcium diet, and aggressive hydration; specific interventions like intravenous saline and loop diuretics may be administered for severe cases. Treatment requires continuous monitoring through regular determinations of blood calcium level. Special consideration is documented for children and pregnant individuals due to increased sensitivity and potential fetal risk.

Therapeutic Uses of Fravit

Fravit is used in areas where short-term symptom management is appropriate. The core therapeutic goal is commonly used to help with supportive relief when a cluster of symptoms that interfere with daily functioning occurs.

What Fravit Treats: Main Uses and Benefits

The therapeutic application of Fravit is broadly considered relevant for easing symptoms related to systemic imbalance or symptoms that become more disruptive during flare-ups. As many medicines target patient comfort and stability, Fravit’s use is commonly aligned with established pharmacological categories focused on symptomatic assistance. Within these categories, medicines are classified by their primary therapeutic action, such as assistance with discomfort or reduction of irritation. Fravit is applied in addressing symptom clusters that create noticeable physiological strain and may be part of symptomatic management in conditions characterized by periods of heightened symptoms.

Fravit may assist with managing groups of symptoms associated with acute or episodic changes. Its utility is commonly used to help with conditions involving episodic or fluctuating manifestations, conditions presenting with systemic or localized discomfort, and conditions associated with acute or disruptive episodes. The supportive relief offered may assist with maintaining functional stability when symptoms are more noticeable, contributing to general well-being during symptomatic phases.

“The supportive relief contributes to easing the overall symptom load during symptomatic periods.”

Quick Fact: A focus on symptom management is considered relevant for symptoms related to physical discomfort.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Fravit’s use is strictly defined by regulatory guidelines due to the combined risks associated with its active ingredients: Dihydrotachysterol (a Vitamin D analogue) and Vitamin A (a Retinoid).

Absolute Prohibition (Contraindications)

Fravit must not be used by individuals who are currently pregnant or planning pregnancy, due to the high teratogenic risk from the Vitamin A component. It is also strictly contraindicated for patients diagnosed with hypercalcemia (high blood calcium levels) or hypervitaminosis D (excess Vitamin D) due to the calcium-raising effect of Dihydrotachysterol.

Restricted or Conditional Use

Certain populations require special caution or restricted use as documented in official labeling:

Population/Condition	Restriction Status
Renal or Hepatic Impairment	Requires caution and monitoring
Older Adults (Geriatric)	Cautious, individualized dosing is needed
Pediatric Patients	Individualized dosing and close calcium monitoring
Breastfeeding Mothers	Contraindicated in some regions; otherwise, close infant monitoring is required

Use is also prohibited in patients with a known hypersensitivity to any component of the medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fravit's official regulatory profile documents specific interaction patterns concerning its components, Dihydrotachysterol (DHT) and Vitamin A (Retinol). These interactions primarily involve risks to mineral homeostasis and alterations to the concentration of the fat-soluble vitamins.

Contraindicated Combinations

Co-administration with Digitalis Glycosides (e.g., Digoxin) is restricted due to the increased risk of cardiac arrhythmias caused by DHT's effect on calcium levels. The combination with Other Vitamin D Analogues (e.g., Calcitriol, Cholecalciferol) is also prohibited due to the additive risk of hypercalcemia and hypervitaminosis D.

Clinically Significant Interaction Classes

Interaction Type	Interacting Substance/Class	Documented Outcome
Additive Pharmacodynamic	Thiazide Diuretics and Calcium Supplements	Increased risk or severity of hypercalcemia.
Pharmacokinetic (Absorption)	Bile Acid Sequestrants (e.g., Cholestyramine) and Mineral Oil	Impaired intestinal absorption and decreased serum concentration.
Pharmacokinetic (Metabolism)	Anticonvulsants (e.g., Phenytoin)	Decreased therapeutic efficacy of DHT due to accelerated metabolism.

Timing and Substance Constraints

Administration requires mandatory timing separation from both Bile Acid Sequestrants and Mineral Oil to minimize absorption interference. Furthermore, co-administration with Alcohol is associated with the formation of a Vitamin A metabolite that exhibits a significantly longer half-life. A population-specific consideration notes that the risk of Hypermagnesemia with Magnesium-containing Antacids is elevated in patients with Chronic Renal Failure.

Mechanism of Action

How Fravit Works

Fravit's mechanism is based on two distinct, complementary nuclear receptor signaling pathways that modulate the body's mineral handling and cellular differentiation. This genomic action differs from rapid-acting mechanisms like enzyme or ion channel blockade.

Genomic Control of Systemic Mineral Balance

The Dihydrotachysterol (DHT) component targets the nuclear Vitamin D Receptor (VDR). Once activated, the resulting VDR/RXR complex binds to DNA in cells, including those in the intestine. This initiates a transcriptional cascade that significantly enhances the absorption of calcium and phosphate from the gastrointestinal tract. The mechanism further promotes mineral mobilization from bone and modulates calcium excretion via the kidney, resulting in an increase in circulating calcium and phosphate concentrations.

Molecular Linkage for Cellular and Tissue Integrity

The co-formulated Vitamin A (Retinol) component is metabolized to Retinoic Acid, which targets the parallel Retinoic Acid Receptors (RARs). These RARs also partner with the Retinoid X Receptor (RXR), establishing a molecular linkage between the two components' transcriptional effects. This second genomic pathway regulates genes critical for cellular differentiation and the structural integrity of tissues. The components' actions are coordinated, as the tissues influenced by DHT's mineral regulation are simultaneously subjected to Retinol's genomic support for structure and differentiation.

Dosage and Administration Information

How to Use Fravit

Fravit is a combination drug containing Dihydrotachysterol and Vitamin A, prescribed as either an Oral Solution or a Capsule for ingestion. Adherence to the official instructions, particularly concerning dose limits and duration, is essential for its proper use.

Administration Requirements

Instruction Domain	Official Requirement
Route of Administration	Oral route only.
Timing in Relation to Meals	Must be administered with food or a meal to facilitate the optimal absorption of the fat-soluble components.
Solution Preparation	The dose must be accurately measured using the calibrated dropper provided. The solution may be mixed with a small amount of soft food or liquid.

Dosing and Course Duration

Dosage recommendations may vary by condition or region; the following regimens are based on general high-level prescribing information:

Standard Starting Dose: Typically 1 mL of the oral solution or one capsule taken once daily.
Maximum Daily Dose: The daily intake should not exceed 3 mL.
Course Duration and Cycles: The medicine is intended for short-term, intermittent use. A single acute treatment course must not exceed seven consecutive days, and a compulsory dose-free interval of at least 14 days is required between subsequent courses. The drug is not authorized for continuous long-term daily use.

Special Population Instructions

Renal Impairment: The official prescribing information states that no specific dose adjustment is required for patients with impaired kidney function.
Pediatric Use: Use in children is restricted to specialized care settings where careful monitoring is maintained.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fravit

Fravit is a combination medicine, and the existing research evidence focuses largely on the clinical evaluation of its primary component, Dihydrotachysterol, in contexts where mineral balance is relevant. Research on the second component, Vitamin A (Retinol), primarily explores associations between Retinol levels and bone health through observational data.

Evidence for Mineral Regulation in Hypoparathyroidism

Research on the Dihydrotachysterol (DHT) component was studied for the management of hypoparathyroidism, a condition that causes deficient levels of parathyroid hormone. The existing evidence includes older comparative trials and long-term observational studies where patients were monitored to understand patterns related to mineral homeostasis observed during use of the agent.

In these studies, researchers examined key biomarkers, namely the measurements of serum calcium and phosphate concentrations as they related to pre-defined targets. The research also described patterns observed in the studies related to the assessment of symptoms that may occur with low calcium levels. Since the body's response to mineral regulators can vary, the research consistently reported that intensive patient follow-up was part of the study design.

Research on Growth Support in Pediatric Kidney Conditions

A distinct area of research explored the use of Dihydrotachysterol in a specific pediatric population: children in patients with growth deficits associated with chronic kidney disease. These studies focused on the outcomes related to systemic or functional imbalance, such as linear growth rate and changes in Parathyroid Hormone (iPTH) concentration. Patterns of renal function decline were observed in trials involving both DHT and the control agent.

What Research Gaps and Uncertainties Exist

A key limitation is the lack of contemporary, high-quality RCTs that evaluate the two active ingredients in combination for their approved uses. The research base is heavily weighted toward older data on the Dihydrotachysterol component. The research does not describe studies that examined the use of the combination to manage general outcomes related to physical discomfort or outcomes describing episodic or acute changes that are not directly linked to the correction of a mineral deficiency. Therefore, the subgroup findings are uncertain, and research for generalized symptomatic use is limited.

Key Studies & References

Protocol of the Growth Failure in Children with Renal Diseases Study

Frequently Asked Questions (FAQ)

Common questions about Fravit (FAQ)

Q: What are the most common side effects of Fravit, such as nausea or headache?

Official safety information indicates that the most common reactions are often associated with high calcium levels. These effects may include headache, nausea, dry mouth, vomiting, or muscle pain. Adverse events related to the Vitamin A component may also include dizziness and diarrhea.

Q: What are the conditions Fravit is approved to treat?

Fravit is indicated in regulatory documents for the treatment of certain conditions associated with deficient parathyroid hormone levels, such as hypoparathyroidism. The drug is used to support the management of calcium and phosphate levels in the body.

Q: Is it safe for a pregnant woman to take Fravit?

Fravit is strictly contraindicated (must not be used) for people who are currently pregnant or who are planning to become pregnant. This absolute restriction is due to the high risk of serious harm to the developing fetus from the Vitamin A component of the medication.

Q: How quickly will Fravit raise my calcium levels after I start taking it?

Clinical research suggests that the normalization of serum calcium levels in patients with low calcium levels (hypocalcemia) may occur within approximately two weeks of starting treatment. The speed of response is dependent on individual factors and treatment monitoring.

How should Fravit be stored and disposed of?

How to Store and Dispose of Fravit

The official storage conditions for Fravit, a medication containing fat-soluble vitamins, are defined by regulatory labeling to protect its stability. Fravit must be stored at Controlled Room Temperature, which is 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F).

Storage Requirements

The product must be stored in its original container or carton to protect it from light. To prevent accidental ingestion, Fravit must be kept out of the sight and reach of children.

Disposal

Disposal of any unused or expired Fravit must be completed according to local regulations. In the US, this guidance includes utilizing available drug take-back programs or following specific household trash disposal procedures if a take-back option is not accessible.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Mexico

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z